Zynteglo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of transfusion-dependent beta-thalassemia, limitations of lifelong blood transfusion therapies, expansion of genetic disease treatment centers, advancements in stem cell modification techniques, early regulatory approvals for gene therapies.

The growth in the forecast period can be attributed to increasing commercialization of gene editing therapies, rising investments in rare disease gene treatments, expansion of personalized medicine infrastructure, growing focus on curative hematology solutions, increasing healthcare funding for genetic disorders. Major trends in the forecast period include increasing adoption of gene therapy for blood disorders, rising use of one-time curative treatments, growing focus on stem cell-based therapies, expansion of personalized genetic medicine, enhanced emphasis on long-term disease correction.

The rising incidence of thalassemia is expected to drive the growth of the Zynteglo market in the coming years. Thalassemia is a group of inherited blood disorders characterized by insufficient hemoglobin production, leading to anemia. The rising incidence of thalassemia is attributed to factors such as high carrier rates in certain populations, genetic inheritance through consanguineous marriages, increased migration, lack of awareness and screening, and improved diagnosis and survival rates. Zynteglo provides a one-time gene therapy that enables patients to produce healthy hemoglobin, potentially eliminating the need for regular blood transfusions. For instance, in November 2024, according to the American Society of Hematology, a US-based professional organization, the prevalence of beta-thalassemia in 2023 was approximately 3,665 cases, corresponding to 1.07 per 100,000 individuals. Therefore, the rising incidence of thalassemia is driving the growth of the Zynteglo market.

The rise in healthcare infrastructure is expected to propel the growth of the Zynteglo market. Healthcare infrastructure refers to the physical facilities, organizational structures, equipment, personnel, and systems necessary to deliver effective healthcare services. The rise in healthcare infrastructure is driven by population growth, medical technology advancements, government investments, the increasing burden of chronic diseases, urbanization, private sector participation, medical tourism, and an aging population. Improved infrastructure supports advanced treatments like Zynteglo by providing comprehensive care from diagnosis to therapy administration. For instance, in January 2025, according to Sports Medical, a UK-based healthcare industry publication, health work starting on site in the UK totaled £4.8 billion in 2024, representing an 18% year-on-year increase from 2023. Therefore, the rise in healthcare infrastructure is driving the growth of the Zynteglo market.

Major companies operating in the Zynteglo market are focusing on technological advancements for commercialization scale-up and real-world implementation of gene therapies. This involves optimizing patient-start processes, supply-chain readiness, and center-of-excellence networks to ensure safe and timely delivery of autologous cell and gene therapies. Commercialization scale-up and real-world implementation refer to the systems, processes, and technologies required to transition a therapy from regulatory approval to routine patient access at scale. For instance, in January 2024, bluebird bio, Inc., a US-based biotechnology company specializing in severe genetic diseases, announced that 26 patient starts were completed in 2023 across its commercial portfolio, including 20 for Zynteglo and 6 for Skysona. This milestone marked a pivotal moment in moving the therapy from approval into meaningful real-world use, providing patients with access to a potentially curative treatment and validating the company’s operational model for patient identification, center coordination, and supply logistics.

Major companies operating in the zynteglo market are Bluebird bio Inc.

North America was the largest region in the zynteglo market in 2025. The regions covered in the zynteglo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zynteglo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zynteglo market by increasing costs of imported viral vectors, cell-processing equipment, specialized reagents, and cold-chain logistics used in gene therapy manufacturing. Treatment centers in North America and Europe are most affected due to reliance on cross-border gene therapy supply chains, while emerging markets face high import-related cost barriers. These tariffs increase overall therapy costs and limit patient access. However, they are also encouraging localized gene therapy manufacturing, regional cell-processing facilities, and investments in domestic advanced therapy production capabilities.

The zynteglo market research report is one of a series of new reports that provides zynteglo market statistics, including zynteglo industry global market size, regional shares, competitors with a zynteglo market share, detailed zynteglo market segments, market trends and opportunities, and any further data you may need to thrive in the zynteglo industry. This zynteglo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zynteglo is a gene therapy used to treat beta-thalassemia, a genetic blood disorder. It works by modifying a patient’s stem cells to produce functional hemoglobin, targeting the underlying cause of the disease. The therapy aims to reduce or eliminate the need for blood transfusions in patients with transfusion-dependent beta-thalassemia.

The primary indications for Zynteglo are beta-thalassemia and sickle cell disease. Beta-thalassemia is a genetic blood disorder in which the body produces insufficient beta-globin, leading to anemia and, in severe cases, requiring interventions such as blood transfusions. Zynteglo is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving adults, children, and elderly patients.

The zynteglo market consists of sales of autologous gene therapy, one-time curative therapy and cell therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.